Turin Lobera & Diub Global v. Injeflex: Appeal Dismissed by São Paulo Court
Enrique Horacio Turin Lobera and Diub Global S.R.L. brought an appeal before the Court of Justice of São Paulo against Injeflex Indústria e Comércio de Dispositivos e Produtos Médicos Ltda, centring on BRPI1312442A2 — a patent covering an intrauterine device designed to increase weight gain and carcass yield in mammals. The appeal was dismissed, leaving the lower-court outcome in place.
São Paulo appellate court closes door on Injeflex patent challenge
The plaintiffs — Enrique Horacio Turin Lobera and Diub Global S.R.L. — initiated proceedings against Injeflex Indústria e Comércio de Dispositivos e Produtos Médicos Ltda, a Brazilian manufacturer of medical devices and products. The dispute centred on BRPI1312442A2, a Brazilian patent application covering an intrauterine device engineered to increase weight gain and carcass yield in mammals, alongside a treating assembly incorporating the device. The case was heard at the Court of Justice of São Paulo under case number 2034531-10.2025.8.26.0000.
The appeal was dismissed by the Court of Justice of São Paulo, with the panel stating: ‘In view of the above, the appeal is dismissed.’ This procedural outcome means the appellate court declined to disturb the lower-level ruling on the merits, and the matter was closed on 11 March 2025. For the appellants, the dismissal represents an exhaustion of this appellate avenue without any substantive review of their claims against Injeflex.
The public record does not disclose the original filing date, the duration of the full proceedings, or the specific grounds on which the appeal was dismissed. The absence of a merits-based ruling suggests the dismissal may have been procedural in nature — a pattern consistent with appeals that fail to meet formal admissibility requirements under Brazilian civil procedure. What drove the original dispute, and whether further review is pursued, remains unclear from available records.
Filing to Appeal Dismissed in 0 days
Case closed 11 March 2025; filing date not on public record
Appeal dismissed: what the São Paulo ruling means for both parties
Appeal dismissed — no merits adjudication at appellate level
A dismissed appeal at the Court of Justice of São Paulo means the appellate panel declined to examine the substance of the appellants’ claims. Under Brazilian procedural law, an appeal can be dismissed for failure to meet admissibility conditions — such as standing, timeliness, or formal requirements — without the court ever addressing the underlying patent dispute. The lower-court decision therefore remains operative by default.
Procedural dismissalAppellants lose their challenge without a substantive ruling
Turin Lobera and Diub Global S.R.L. did not obtain a merits-based ruling on their appeal. The dismissal closes this specific appellate pathway. Depending on the grounds for dismissal, the appellants may still have recourse to superior courts — such as the Superior Tribunal de Justiça — if a question of federal law or admissibility error can be demonstrated, though the public record is silent on whether further action is planned.
Appeal avenue closedInjeflex prevails procedurally; lower ruling preserved
For Injeflex, the dismissal of the appeal is a favourable procedural result: the lower-court decision stands, and the respondent avoids a substantive appellate examination of the patent dispute. However, because the dismissal is procedural rather than on the merits, it does not constitute a definitive judicial pronouncement on the validity or infringement of BRPI1312442A2, which could leave residual uncertainty if appellants seek alternative routes.
Lower ruling intactUnresolved merits create lingering IP uncertainty in veterinary device sector
Because the appeal was dismissed on procedural rather than substantive grounds, the core patent questions around BRPI1312442A2 — covering intrauterine devices for mammalian weight gain and carcass yield — remain unanswered judicially. Competitors and investors in the veterinary medical device and livestock management sector should note that this outcome does not clarify the patent’s enforceability or scope, suggesting ongoing freedom-to-operate risk until a merits ruling is issued or the patent lapses.
FTO risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ENRIQUE HORACIO TURIN LOBERA AND DIUB GLOBAL S.R.L. | Individual | Patent applicants and rights claimants — holders of BRPI1312442A2 for mammalian intrauterine devicesSearch in Eureka ↗ |
| Defendant | INJEFLEX INDÚSTRIA AND COMÉRCIO DE DISPOSITIVOS AND PRODUTOS MÉDICOS LTDA | Individual | Brazilian manufacturer of medical devices and products; respondent in the São Paulo appealSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The panel’s ruling — ‘the appeal is dismissed’ — is a terse procedural disposition that forecloses appellate review without engaging the patent’s merits. Under Brazilian appellate procedure, such language typically indicates a failure of admissibility rather than a substantive defeat. The verdict leaves the lower-court outcome intact for Injeflex but provides no judicial clarity on the validity or infringement of BRPI1312442A2, preserving uncertainty for both parties and the broader veterinary device market.
BRPI1312442A2 — intrauterine device for mammalian weight gain and carcass yield
BRPI1312442A2 is a Brazilian patent application covering an intrauterine device specifically engineered to increase weight gain and improve carcass yield in mammals, together with a treating assembly that incorporates the device. The technology sits at the intersection of veterinary medicine and livestock productivity, targeting implantable delivery systems for growth-enhancing applications in animal husbandry. The ‘BRPI’ prefix designates it as a Brazilian national phase patent application, and the ’13’ series number suggests an application originating around 2013.
For the Brazilian livestock and veterinary device sector, BRPI1312442A2 represents a potentially significant IP asset given Brazil’s position as a global leader in beef and livestock production. Any company developing or commercialising intrauterine implants, veterinary delivery systems, or growth-promoting technologies for cattle, swine, or other mammals should assess this patent’s claim scope carefully. The unresolved litigation between Diub Global and Injeflex — a commercial medical device manufacturer — suggests active commercial tension over the technology.
Should you run an FTO analysis against BRPI1312442A2?
Any manufacturer, distributor, or R&D team working on intrauterine delivery devices for veterinary or livestock applications in Brazil should assess exposure to BRPI1312442A2. Given the patent application’s focus on mammalian weight gain and carcass yield improvement, companies active in growth-promoting implants, hormonal delivery systems for livestock, or veterinary treating assemblies face potential overlap risk — particularly in Brazil’s commercially critical beef and dairy sectors.
PatSnap Eureka’s FTO Search Agent can map BRPI1312442A2’s claim landscape against your product specifications, flag related Brazilian and international filings by Diub Global S.R.L. and Turin Lobera, and surface any continuation or divisional applications that may extend this patent family’s reach. With the litigation unresolved on the merits, proactive FTO analysis is the most reliable way to quantify and manage your exposure before entering or expanding in this product category.
Run a freedom-to-operate analysis on BRPI1312442A2 to assess your product’s exposure
Run FTO in Eureka →Similar patent disputes: intrauterine and veterinary device IP in Brazilian courts
Explore comparable patent litigation involving veterinary implants, intrauterine devices, and livestock technology at the Court of Justice of São Paulo and Brazilian federal tribunals.
What this case signals for the veterinary medical device IP landscape
A procedural dismissal in São Paulo leaves the patent’s enforceability unresolved — a signal worth monitoring for livestock and veterinary device players.
Procedural dismissals do not settle patent validity — monitor BRPI1312442A2
The appeal’s dismissal without merits review means no court has definitively ruled on whether BRPI1312442A2 is valid or infringed. Companies operating in mammalian growth-enhancing devices or veterinary implants should treat this patent as an active risk until a substantive ruling or expiry occurs.
Brazilian appellate procedure can terminate cases without substantive IP analysis
Under Brazilian civil procedure, appeals face strict admissibility filters. This case illustrates that patent disputes can close at the appellate level without any judicial assessment of the underlying technology claims — a dynamic that favours incumbents and complicates rights enforcement for challengers.
S.R.L. v INJEFLEX — key questions answered
The appeal dismissal is procedural, not substantive. The Court of Justice of São Paulo declined to review the merits of the dispute, leaving the lower-court ruling intact. No judicial determination was made on the validity or infringement of BRPI1312442A2, meaning the patent’s enforceability remains legally unresolved.
BRPI1312442A2 is a Brazilian patent application covering an intrauterine device designed to increase weight gain and carcass yield in mammals, along with a treating assembly incorporating the device. It targets veterinary and livestock productivity applications, particularly relevant to Brazil’s large-scale cattle and animal husbandry industries.
Potentially yes. Under Brazilian law, a party whose state appellate appeal is dismissed may be able to escalate to the Superior Tribunal de Justiça (STJ) if the grounds involve a question of federal law, or to the Supreme Federal Tribunal (STF) on constitutional grounds. However, the public record is silent on whether further action has been or will be pursued.
The plaintiffs-appellants are Enrique Horacio Turin Lobera and Diub Global S.R.L., the patent applicant and rights claimant. The defendant-respondent is Injeflex Indústria e Comércio de Dispositivos e Produtos Médicos Ltda, a Brazilian manufacturer of medical devices and products. The case was heard at the Court of Justice of São Paulo.
The dismissal does not resolve the underlying patent dispute, so freedom-to-operate risk around BRPI1312442A2 persists. Companies developing or selling intrauterine devices for mammalian weight gain or carcass yield improvement in Brazil should conduct a formal FTO analysis, as no court has ruled definitively on the patent’s validity or scope.
PatSnap Eureka searches patents and litigation data to answer instantly.